vTv Therapeutics (FRA:5VT0) Cyclically Adjusted PB Ratio: (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
35 GF Score
Price €27.40
GF Value €6,522.76
View Full Analysis

What is vTv Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


vTv Therapeutics  (FRA:5VT0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


vTv Therapeutics Cyclically Adjusted PB Ratio Related Terms


vTv Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics Cyclically Adjusted PB Ratio Chart

vTv Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

vTv Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:5VT0 vs SMNR, CNTB, ENLV: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, vTv Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:5VT0
35GF Score
vTv Therapeutics Inc FRA:5VT0
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

vTv Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

vTv Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, vTv Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=19.755/330.2130*330.2130
=19.755

Current CPI (Mar. 2026) = 330.2130.

vTv Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 -292.450 241.018 -400.679
201609 -409.566 241.428 -560.184
201612 -356.264 241.432 -487.272
201703 -477.041 243.801 -646.122
201706 -391.343 244.955 -527.552
201709 -472.554 246.819 -632.218
201712 -527.417 246.524 -706.462
201803 -496.572 249.554 -657.070
201806 -225.320 251.989 -295.265
201809 -95.657 252.439 -125.128
201812 -143.081 251.233 -188.061
201903 -75.029 254.202 -97.464
201906 -59.200 256.143 -76.319
201909 -48.319 256.759 -62.142
201912 -43.129 256.974 -55.421
202003 -50.088 258.115 -64.079
202006 -51.494 257.797 -65.959
202009 -35.488 260.280 -45.023
202012 -48.737 260.474 -61.786
202103 -32.850 264.877 -40.953
202106 -26.374 271.696 -32.054
202109 -11.019 274.310 -13.265
202112 -5.149 278.802 -6.098
202203 -4.389 287.504 -5.041
202206 -4.173 296.311 -4.650
202209 -8.216 296.808 -9.141
202212 -4.977 296.797 -5.537
202303 -8.800 301.836 -9.627
202306 -11.456 305.109 -12.399
202309 -11.607 307.789 -12.453
202312 -10.855 306.746 -11.685
202403 7.864 312.332 8.314
202406 6.291 314.175 6.612
202409 5.177 315.301 5.422
202412 4.460 315.605 4.666
202503 2.805 319.799 2.896
202506 0.915 322.561 0.937
202509 15.262 324.800 15.516
202512 13.970 324.054 14.236
202603 19.755 330.213 19.755

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €27.40 is trading 99.6% below its estimated GF Value™ of €6,522.76.

Key valuation signals for FRA:5VT0:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €6,522.76 vs. price of €27.40 (99.6% below fair value)
  • GF Score™: 35/100

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for FRA:5VT0

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.40
Price
€6,522.76
GF Value